Grossbard E B
Department of Clinical Research, Genentech, Inc., South San Francisco, California 94080.
Pharm Res. 1987 Oct;4(5):375-8. doi: 10.1023/a:1016474026501.
Thrombolytic therapy has received renewed attention with the demonstration that early treatment of acute myocardial infarction with plasminogen activators can reduce mortality. Tissue plasminogen activator (t-PA) is a protein with attributes that may allow for greater efficacy and safety. Recombinant DNA technology has enabled the production of sufficient t-PA, called rt-PA (Activase), for substantial clinical evaluation. The results suggest that Activase is a significant advance in thrombolytic therapy.
随着有证据表明用纤溶酶原激活剂对急性心肌梗死进行早期治疗可降低死亡率，溶栓疗法再次受到关注。组织纤溶酶原激活剂（t-PA）是一种具有可能带来更高疗效和安全性特性的蛋白质。重组DNA技术已能够生产足够量的t-PA，即重组t-PA（阿替普酶），用于大规模临床评估。结果表明，阿替普酶是溶栓治疗方面的一项重大进展。
